Section of Hepatology and Gastroenterology, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom.
Institute of Liver Studies, Department of Inflammation Biology, School of Immunology and Microbial Sciences, King's College London, London, United Kingdom.
Semin Liver Dis. 2023 Nov;43(4):402-417. doi: 10.1055/s-0043-1776761. Epub 2023 Dec 15.
In recent years cancer treatment has been revolutionized by the development and wide application of checkpoint inhibitor (CPI) drugs, which are a form of immunotherapy. CPI treatment is associated with immune-related adverse events, off-target tissue destructive inflammatory complications, which may affect a range of organs, with liver inflammation (hepatitis) being one of the more commonly noted events. This is a novel form of drug-induced liver injury and a rapidly evolving field, as our understanding of both the basic immunopathology of CPI hepatitis (CPI-H) and optimal clinical management, races to catch up with the increasing application of this form of immunotherapy in clinical practice. In this review, we summarize current evidence and understanding of CPI-H, from fundamental immunology to practical patient management.
近年来，随着检查点抑制剂（CPI）药物的发展和广泛应用，癌症治疗发生了革命性变化，CPI 药物属于免疫疗法的一种。CPI 治疗与免疫相关的不良反应、非靶向组织破坏性炎症并发症相关，可能影响一系列器官，肝炎症（肝炎）是更常见的事件之一。这是一种新型的药物性肝损伤，是一个迅速发展的领域，我们对 CPI 肝炎（CPI-H）的基础免疫病理学和最佳临床管理的理解正在迅速赶上这种免疫疗法在临床实践中的应用日益增多。在这篇综述中，我们总结了从基础免疫学到实际患者管理的 CPI-H 的现有证据和认识。
